Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Chronic hyperglycemia impairs insulin action, resulting in glucotoxicity, which can be ameliorated in animal models by inducing glucosuria with renal glucose transport inhibitors. Here, we examined whether reduction of plasma glucose with a sodium-glucose cotransporter 2 (SGLT2) inhibitor could improve insulin-mediated tissue glucose disposal in patients with type 2 diabetes. Eighteen diabetic men were randomized to receive either dapagliflozin (n = 12) or placebo (n = 6) for 2 weeks. We measured insulin-mediated whole body glucose uptake and endogenous glucose production (EGP) at baseline and 2 weeks after treatment using the euglycemic hyperinsulinemic clamp technique. Dapagliflozin treatment induced glucosuria and markedly lowered fasting plasma glucose. Insulin-mediated tissue glucose disposal increased by approximately 18% after 2 weeks of dapagliflozin treatment, while placebo-treated subjects had no change in insulin sensitivity. Surprisingly, following dapagliflozin treatment, EGP increased substantially and was accompanied by an increase in fasting plasma glucagon concentration. Together, our data indicate that reduction of plasma glucose with an agent that works specifically on the kidney to induce glucosuria improves muscle insulin sensitivity. However, glucosuria induction following SGLT2 inhibition is associated with a paradoxical increase in EGP. These results provide support for the glucotoxicity hypothesis, which suggests that chronic hyperglycemia impairs insulin action in individuals with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Long-term effects of sodium-glucose transport protein 2 inhibitors (SGLT2i) might enhance insulin sensitivity, thereby mitigating muscle catabolism and influencing the quality and functionality of the skeletal muscle.30,31”
From Imaging of Sarcopenia in Type 2 Diabetes Mellitus (2024) · cites this paper as [31]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glucose clamp technique: a method for quantifying insulin secretion and resistance.
DeFronzo, R. A., Tobin, J. D., & Andres, R. (1979) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1979.237.3.e214 · Cited by 7,425 · cited 2×
“After the start of insulin, no glucose was infused until the plasma glucose concentration declined to 100 mg/dl, at which level it was maintained by the adjustment of a variable glucose infusion based on the negative feedback principle (27).”
Self-citationDeFronzo, R. A., Jacot, E., Jequier, E., Maeder, E., Wahren, J., & Felber, J. P. (1981) · Diabetes · doi:10.2337/diab.30.12.1000 · Cited by 1,770 · cited 1×
“Since >80% of insulin-mediated glucose disposal during the euglycemic insulin clamp takes place in skeletal muscle (16), these results indicate that lowering the plasma glucose concentration in T2DM significantly improves muscle insulin resistance and are consistent with a glucotoxic effect of chronic hyperglycemia to…”
Self-citationMeasurement of Size and Turnover Rate of Body Glucose Pool by the Isotope Dilution Method
Steele, R., Wall, J. S., de Bodo, R. C., & Altszuler, N. (1956) · American Journal of Physiology-Legacy Content · doi:10.1152/ajplegacy.1956.187.1.15 · Cited by 816 · cited 1×
“After drug administration and during the insulin clamp, nonsteady-state conditions for 3-3 H-glucose–specific activity prevail and the rate of glucose appearance ( R a ) was calculated with Steele’s equation (28).”
Groop, L. C., Bonadonna, R. C., DelPrato, S., Ratheiser, K., Zyck, K., Ferrannini, E., & DeFronzo, R. A. (1989) · Journal of Clinical Investigation · doi:10.1172/jci114142 · Cited by 812 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citationRossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Self-citationRossetti, L., Giaccari, A., & DeFronzo, R. A. (1990) · Diabetes Care · doi:10.2337/diacare.13.6.610 · Cited by 770
Self-citationDeFronzo, R. A., Ferrannini, E., & Simonson, D. C. (1989) · Metabolism · doi:10.1016/0026-0495(89)90129-7 · Cited by 515 · cited 1×
“Because of the close relationship between EGP (primarily reflects liver) and the fasting plasma glucose concentration (17), the decrease in FPG brought about by dapagliflozin would be expected to be associated with a decrease in HGP.”
Self-citationBanting Lecture 1997. Control of glucose uptake and release by the liver in vivo.
Cherrington, A. D. (1999) · Diabetes · doi:10.2337/diabetes.48.5.1198 · Cited by 502
Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes
Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0029 · Cited by 443 · cited 1×
“…the impact of chronic hyperglycemia on insulin sensitivity in individuals with T2DM, we examined the effect of lowering the plasma glucose concentration on whole body insulin sensitivity by inhibiting renal sodium-glucose cotransport with dapagliflozin (15) using the insulin clamp technique.”
Self-citationDose-Response Effect of Elevated Plasma Free Fatty Acid on Insulin Signaling
Belfort, R., Mandarino, L., Kashyap, S., Wirfel, K., Pratipanawatr, T., Berria, R., DeFronzo, R. A., & Cusi, K. (2005) · Diabetes · doi:10.2337/diabetes.54.6.1640 · Cited by 404 · cited 1×
“However, these latter studies are difficult to interpret, since insulin therapy also exerts other metabolic effects, e.g., reduction in plasma free fatty acid concentration (12), which profoundly affect insulin sensitivity independent of changes in plasma glucose concentration (13).”
Self-citation
Research works printed but not linked: 1
- Del Prato S, Leonetti F, Simonson DC, Sheehan P, Matsuda M, DeFronzo RA. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man. Diabetologia. 1994;37(10):1025-1035. · DOI · Paper page
Cited by
Items 201–300 of 789
SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
Škrabić, R., Kumrić, M., Vrdoljak, J., Rušić, D., Skrabic, I., Vilović, M., Martinović, D., Duplancic, V., Kurir, T. T., & Božić, J. (2022) · Biomedicines · doi:10.3390/biomedicines10102458 · Cited by 60
Peng, X., Gennemark, P., O’Mahony, G., & Bartesaghi, S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00174 · Cited by 57
“To place this in a pharmacological context, this improvement in insulin sensitivity is similar in extent to that seen after 2-week treatment with dapagliflozin (Farxiga/Forxiga), which affords an 18% improvement in tissue glucose disposal (44).”
ResultBajaj, H. S., Brown, R. E., Bhullar, L., Sohi, N., Kalra, S., & Aronson, R. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.08.001 · Cited by 50
Sarcopenia – Endocrinological and Neurological Aspects
Stangl, M. K., Böcker, W., Chubanov, V., Ferrari, U., Fischereder, M., Gudermann, T. W., Hesse, E., Meinke, P., Reincke, M., Reisch, N., et al. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-0672-1007 · Cited by 68
“…not well studied regarding muscle integrity, but two weeks of dapagliflozin treat - ment increased insulin-mediated tissue glucose uptake by 18 % [40] and another study found an overall weight loss without reduction of muscle mass in 50 participants with T2D treated with dapagli-flozin,…”
Kaneto, H., Obata, A., Kimura, T., Shimoda, M., Kinoshita, T., Matsuoka, T., & Kaku, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063062 · Cited by 50
Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts
Chu, Y., Zhang, C., & Xie, M. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.681513 · Cited by 52
Insulin Resistance and High Blood Pressure: Mechanistic Insight on the Role of the Kidney
Brosolo, G., Porto, A. D., Bulfone, L., Vacca, A., Bertin, N., Scandolin, L., Catena, C., & Sechi, L. A. (2022) · Biomedicines · doi:10.3390/biomedicines10102374 · Cited by 66
The Insulin:Glucagon Ratio and the Choice of Glucose-Lowering Drugs
Kalra, S., & Gupta, Y. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0160-4 · Cited by 58
Ishihara, H., Yamaguchi, S., Nakao, I., Okitsu, A., & Asahina, S. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12745 · Cited by 54
SGLT2 inhibition and glucagon secretion in humans
Saponaro, C., Pattou, F., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 49
Abdul-Ghani, M. A. (2015) · Diabetes Care · doi:10.2337/dc14-2517 · Cited by 49
“Although the signal responsible for mediating the increase in glucosuria and the increase in EGP remains to be determined, the increase in EGP was accompanied with a small decrease in plasma insulin concentration and a large increase in plasma glucagon concentration (8,9).”
InfluentialSelf-citationO’Brien, T. P., Jenkins, E. C., Estes, S. K., Castaneda, A. V., Ueta, K., Farmer, T. D., Puglisi, A. E., Swift, L. L., Printz, R. L., & Shiota, M. (2017) · Diabetes · doi:10.2337/db16-1410 · Cited by 48
Veelen, A., Erazo‐Tapia, E., Oscarsson, J., & Schrauwen, P. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101158 · Cited by 53
Mori, Y., Duru, O. K., Tuttle, K. R., Fukuma, S., Taura, D., Harada, N., Inagaki, N., & Inoue, K. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac591 · Cited by 55
Veelen, A., Andriessen, C., den Kamp, Y. J. M. O., Erazo‐Tapia, E., de Ligt, M., Mevenkamp, J., Jörgensen, J. A., Moonen‐Kornips, E., Schaart, G., ESTERLINE, R. L., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155396 · Cited by 52
SGLT-2 inhibition and glucagon: Cause for alarm?
Kibbey, R. G. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.05.011 · Cited by 47
“The initial difference in EGP was driven by a sudden drop in EGP in the placebo group rather than an increase in the treatment arm, and could not be fully explained by measured insulin, glucagon or glucose [1].”
BackgroundMcGill, J. B. (2014) · Diabetes Therapy · doi:10.1007/s13300-014-0063-1 · Cited by 56
“It has been suggested that combination therapy with an agent that inhibits glucagon by increasing incretins (a GLP-1 mimetic or DPP-4 inhibitor) may give synergistic effects for the treatment of hyperglycemia, but this work is still at early stages, and additional studies are needed [16].”
Stein, P., Berg, J. K., Morrow, L., Polidori, D., Artis, E., Rusch, S., Vaccaro, N., & Devineni, D. (2014) · Metabolism · doi:10.1016/j.metabol.2014.07.003 · Cited by 47
“[16] Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al.”
Merovci, A., Abdul‐Ghani, M. A., Mari, A., Solis‐Herrera, C., Xiong, J., Daniele, G., Tripathy, D., & DeFronzo, R. A. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2597 · Cited by 51
Self-citationRahman, A., Hitomi, H., & Nishiyama, A. (2017) · Hypertension Research · doi:10.1038/hr.2016.193 · Cited by 50
Yang, Y., Zhao, C., Ye, Y., Yu, M., & Qu, X. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00190 · Cited by 54
Relative Hypoxia and Early Diabetic Kidney Disease in Type 1 Diabetes
VINOVSKIS, C. L., Li, L., Prasad, P. V., Tommerdahl, K. L., Pyle, L. L., Nelson, R. G., Pavkov, M. E., van Raalte, D. H., Rewers, M., Pragnell, M., et al. (2020) · Diabetes · doi:10.2337/db20-0457 · Cited by 47
The Role of SGLT2 Inhibitor on the Treatment of Diabetic Retinopathy
Sha, W., Wen, S., Chen, L., Xu, B., Lei, T., & Zhou, L. (2020) · Journal of Diabetes Research · doi:10.1155/2020/8867875 · Cited by 55
de Leeuw, A. E., & de Boer, R. A. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw009 · Cited by 46
“Other beneficial findings on SGLT2 inhibition are improvement of pancreatic b-cell function concerning glucose sensitivity,(91) cell mass and overall function,(91) – 95 and improvement in insulin sensitivity and associated peripheral glucose uptake.(91,93,96,97) SGLT2 inhibition also appears to directly affect pancrea…”
Backgroundden Kamp, Y. J. M. O., Gemmink, A., de Ligt, M., Dautzenberg, B., Moonen‐Kornips, E., Jörgensen, J. A., Schaart, G., ESTERLINE, R. L., Pava, D., Hoeks, J., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101620 · Cited by 50
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 76
“During this period, body weight declined modestly from baseline in the dapagliflozin-treated group (−1.2 ± 0.3 kg) 59 , indicating that glycosuria is responsible for the weight loss.”
InfluentialParadoxical insights into whole body metabolic adaptations following SGLT2 inhibition
Cefalu, W. T. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74297 · Cited by 46
“In agreement with Merovci et al. (6), Ferrannini and colleagues also found that SGLT2 inhibition (in this case with empagliflozin) increases EGP.”
BackgroundInfluentialType 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion
Hattersley, A. T., & Thorens, B. (2015) · New England Journal of Medicine · doi:10.1056/nejmcibr1506573 · Cited by 57
Nomoto, H., Miyoshi, H., Sugawara, H., Ono, K., Yanagiya, S., Oita, M., Nakamura, A., & Atsumi, T. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0255-8 · Cited by 46
Koike, Y., Shirabe, S.-I., Maeda, H., Yoshimoto, A., Arai, K., Kumakura, A., Hirao, K., & Terauchi, Y. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.01.029 · Cited by 46
Ali, A. M., Martinez, R., Al-Jobori, H., Adams, J., Triplitt, C., DeFronzo, R., Cersosimo, E., & Abdul-Ghani, M. (2020) · Diabetes Care · doi:10.2337/dc18-2460 · Cited by 46
Self-citationSo, A., Sakaguchi, K., Okada, Y., Morita, Y., Yamada, T., Miura, H., Otowa-Suematsu, N., Nakamura, T., Komada, H., Hirota, Y., et al. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej19-0445 · Cited by 45
Dapagliflozin in patients with type 2 diabetes mellitus
Filippatos, T. D., Liberopoulos, E. N., & Elisaf, M. (2014) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018814558243 · Cited by 52
Oh, T. J., Sul, W. J., Oh, H. N., Lee, Y.-K., Lim, H. L., Choi, S. H., Park, K. S., & Jang, H. C. (2019) · Scientific Reports · doi:10.1038/s41598-019-56684-5 · Cited by 50
Horii, T., Oikawa, Y., Kunisada, N., Shimada, A., & Atsuda, K. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001856 · Cited by 57
“24 25 Thus, the risk of hypoglycemia from SGLT2 inhibitors is low; in several meta-analyses of randomized controlled trials (RCTs), the authors reported that the risk of hypoglycemia when SGLT2 P values were calculated for differences between patients with and without hypoglycemic events.”
Nutrition and Obesity in the Pathogenesis of Youth-Onset Type 1 Diabetes and Its Complications
March, C. A., BECKER, D. J., & Libman, I. M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.622901 · Cited by 53
Piccirillo, F., Mastroberardino, S., Nusca, A., Frau, L., Guarino, L., Napoli, N., Ussia, G. P., & Grigioni, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241210164 · Cited by 58
SGLT2 inhibitors: a focus on cardiac benefits and potential mechanisms
Muric, M. D., Zivkovic, V. I., Joksimović, J., Sretenovic, J. Z., Davidović, G., Simovic, S. M., Djoković, D., Muric, N. N., Bolevich, S., & Jakovljevic, V. L. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10079-9 · Cited by 49
Wang, X., Ni, J., Guo, R., Li, L., Su, J., He, F., & Fan, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10096-8 · Cited by 49
NIRANJAN, S., Phillips, B. E., & Giannoukakis, N. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1193373 · Cited by 51
Gilbert, R. E., Mende, C. W., Vijapurkar, U., Sha, S., Davies, M. J., & Desai, M. G. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0232-0 · Cited by 44
Dapagliflozin Aggravates Renal Injury via Promoting Gluconeogenesis in db/db Mice
Jia, Y., He, J., Wang, L., Su, L., Lei, L., Huang, W., Geng, X., Zhang, S., Meng, X., Zhou, H., et al. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000487783 · Cited by 44
Kawamori, R., Haneda, M., Suzaki, K., Cheng, G., Shiki, K., Miyamoto, Y., Solimando, F., Lee, C., Lee, J., & George, J. T. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13352 · Cited by 49
Effect of Chronic Hyperglycemia on Glucose Metabolism in Subjects With Normal Glucose Tolerance
Shannon, C. E., Merovci, A., Xiong, J., Tripathy, D., Lorenzo, F., McClain, D. A., Abdul-Ghani, M. A., Norton, L., & DeFronzo, R. A. (2018) · Diabetes · doi:10.2337/db18-0439 · Cited by 44
Self-citationPeptides in the regulation of glucagon secretion
Andersen, D. B., & Holst, J. J. (2022) · Peptides · doi:10.1016/j.peptides.2021.170683 · Cited by 43
“SGLT2 is interesting in the scope of glucagon regulation as SGLT2 inhibitors are widely used in diabetes treatment, and studies have associated SGLT2 inhibitors with an increase in glucagon secretion[29],[30],[31].”
Insulin resistance, role of metformin and other non-insulin therapies in pediatric type 1 diabetes
Bacha, F. F., & Bartz, S. K. (2015) · Pediatric Diabetes · doi:10.1111/pedi.12337 · Cited by 46
The Role of Glucagon in the Pathophysiology and Management of Diabetes
Kulina, G., & Rayfield, E. J. (2016) · Endocrine Practice · doi:10.4158/ep15984.ra · Cited by 51
Tosaki, T., Kamiya, H., Himeno, T., Kato, Y., Kondo, M., Toyota, K., Nishida, T., Shiroma, M., Tsubonaka, K., Asai, H., et al. (2017) · Internal Medicine · doi:10.2169/internalmedicine.56.7196 · Cited by 49
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 45
Effects of SGLT2 inhibition on lipid transport in adipose tissue in type 2 diabetes
Lauritsen, K. M., Voigt, J. H., Pedersen, S. B., Hansen, T. K., Møller, N., Jessen, N., Gormsen, L. C., & Søndergaard, E. (2022) · Endocrine Connections · doi:10.1530/ec-21-0558 · Cited by 45
“However, as reported above, skeletal muscle insulin sensitivity improves rather than deteriorates during SGLT2 inhibitor treatment (28).”
Lavernia, F., Adkins, S. E., & Shubrook, J. H. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1085293 · Cited by 47
“The precise cause of DKA in patients receiving SGLT2 inhibitors is not yet known, but several mechanisms may be involved [67]; for example, a reduction in insulin dose to reduce the risk of hypoglycemia when given in combination therapy with SGLT2 inhibitors may be insufficient to suppress lipolysis and ketogenesis; S…”
BackgroundNeschen, S., Scheerer, M., Seelig, A., Huypens, P., Schultheiss, J., Wu, M., Wurst, W., Rathkolb, B., Suhre, K., Wolf, E., et al. (2015) · Diabetes · doi:10.2337/db14-0393 · Cited by 40
“However, SGLT2Is impede their glucose-lowering effects by enhancing endogenous glucose production in diabetic rats and humans (11,12,19).”
The cardiovascular benefits of empagliflozin: SGLT2-dependent and -independent effects
Vettor, R., Inzucchi, S. E., & Fioretto, P. (2017) · Diabetologia · doi:10.1007/s00125-016-4194-y · Cited by 42
“from 10% to 20% [8, 9]), proposed to play a possible role in cardiovascular protection.”
Tofogliflozin decreases body fat mass and improves peripheral insulin resistance
Matsuba, R., Matsuba, I., Shimokawa, M., Nagai, Y., & Tanaka, Y. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13211 · Cited by 40
Rossing, P. R., Inzucchi, S. E., Vart, P., Jongs, N., Docherty, K. F., Jhund, P. S., Køber, L., Kosiborod, M., Martínez, F. A., Ponikowski, P. P., et al. (2022) · UCL Discovery (University College London) · Cited by 40
Bai, Y., Chi, K., Zhao, D., Shen, W., Liu, R., Hao, J., Cai, G., Chen, X., & Hong, Q. (2024) · Journal of Translational Internal Medicine · doi:10.2478/jtim-2023-0130 · Cited by 48
Storgaard, H., Bagger, J. I., Knop, F. K., Vilsbøll, T., & Rungby, J. (2016) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12457 · Cited by 39
Sodium-glucose co-transporter-2 inhibitors and euglycemic ketoacidosis: Wisdom of hindsight
Singh, A. (2015) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.167554 · Cited by 39
“This finding overall suggests, approximately 23% increase in glucagon/ insulin ratio in dapagliflozin group.[36] Ferrannini et al.”
Chronic Kidney Disease-Induced Insulin Resistance: Current State of the Field
Dave, N., Wu, J., & Thomas, S. S. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1010-8 · Cited by 41
Alatrach, M., Laichuthai, N., MARTINEZ, R. A., Agyin, C., Ali, A. M., Jobori, H. A., Lavynenko, O., Adams, J. M., Triplitt, C. L., DeFronzo, R. A., et al. (2020) · Diabetes · doi:10.2337/db19-0770 · Cited by 40
Self-citationSodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Afşar, B., & Afşar, R. E. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.10.004 · Cited by 44
Sharma, M. D. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12451 · Cited by 44
“It has been estimated that the increase in endogenous glucose production offsets approximately half of the glucose excreted as a result of SGLT2 inhibition with dapagliflozin [41].”
InfluentialWhite, J. R. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015573564 · Cited by 40
Positioning SGLT2 Inhibitors/Incretin-Based Therapies in the Treatment Algorithm
Wilding, J. P. H., Rajeev, S. P., & DeFronzo, R. A. (2016) · Diabetes Care · doi:10.2337/dcs15-3005 · Cited by 43
Self-citationScheen, A. J. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0498-9 · Cited by 39
“However, treatment with SGLT2Is resulted in an increase in plasma glucagon concentrations, which was accompanied by a substantial increase in endogenous (hepatic) glucose production [11, 12].”
Sotagliflozin as a potential treatment for type 2 diabetes mellitus
Cariou, B., & Charbonnel, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1100361 · Cited by 37
“It has been recently demonstrated that SGLT2 inhibitors directly act on α-cells to stimulate glucagon secretion,[54] leading to an increase in hepatic glucose production.[55] This neutral effect of sotagliflozin on glucagon signaling should be confirmed in clamp studies and could be linked either to partial SGLT2 inhi…”
BackgroundSGLT2 inhibition and heart failure—current concepts
da Silva, J. C., Durães, A. R., Abreu, M., Rocha, N. A., & Roever, L. (2018) · Heart Failure Reviews · doi:10.1007/s10741-018-9703-2 · Cited by 44
Trnovská, J., Svoboda, P., Pelantová, H., Kuzma, M., Kratochvílová, H., Kasperová, B. J., Pleyerová, I., ROSOLOVÁ, K., Malínská, H., Hüttl, M., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910606 · Cited by 41
Yan, H., Huang, C., Shen, X., Li, J., Zhou, S., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923606 · Cited by 38
Hattori, S. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12781 · Cited by 37
Palanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 48
Brunton, S. (2015) · International Journal of Clinical Practice · doi:10.1111/ijcp.12675 · Cited by 45
Saponaro, C., Gmyr, V., Thévenet, J., Moerman, E., Delalleau, N., Pasquetti, G., Coddeville, A., Quenon, A., Daoudi, M., Hubert, T., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.009 · Cited by 36
Improvement of skeletal muscle insulin sensitivity by 1 week of SGLT2 inhibitor use
Goto, Y., Otsuka, Y., Ashida, K., Nagayama, A., Hasuzawa, N., Iwata, S., Hara, K., Tsuruta, M., Wada, N., Motomura, S., et al. (2020) · Endocrine Connections · doi:10.1530/ec-20-0082 · Cited by 39
Daniele, G., Solis‐Herrera, C., Dardano, A., Mari, A., Tura, A., Giusti, L., Kurumthodathu, J. J., Campi, B., Saba, A., Bianchi, A. M., et al. (2020) · Diabetologia · doi:10.1007/s00125-020-05254-w · Cited by 37
Self-citationNovel Molecular Evidence Related to COVID-19 in Patients with Diabetes Mellitus
Liao, Y., Zheng, J., Zheng, C., Lu, K., & Chao, Y. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9123962 · Cited by 37
Han, E., Shin, E., Kim, G., Lee, J.-Y., Lee, Y., Lee, B., Kang, E. S., & Soo, B. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00412 · Cited by 37
Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities
Pandey, A., Alcaraz, M., Saggese, P., Soto, A., Gomez, E., Jaldu, S., Yanagawa, J., & Scafoglio, C. (2025) · Cancers · doi:10.3390/cancers17030466 · Cited by 52
“Compensatory hepatic gluconeogenesis, occurring both in normal subjects and diabetic patients, prevents the development of hypoglycemia [31,32].”
Schernthaner, G., Schernthaner-Reiter, M. H., & Schernthaner, G.-H. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.04.037 · Cited by 40
Koufakis, T., Mustafa, O. G., Ajjan, R., García–Moll, X., Zebekakis, P. E., Dimitriadis, G., & Kotsa, K. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13107 · Cited by 36
David-Silva, A., Esteves, J. V. D. C., Morais, M., Freitas, H. S., Zorn, T. M. T., Corrêa‐Giannella, M. L., & Machado, U. F. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s242282 · Cited by 38
Tanday, N., Irwin, N., Flatt, P. R., & Moffett, R. C. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114009 · Cited by 36
Joannides, C. N., Mangiafico, S. P., Waters, M. F., Lamont, B. J., & Andrikopoulos, S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12923 · Cited by 37
Lajara, R. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.968551 · Cited by 35
“Based on their mechanism of action, SGLT2 inhibitors would not be expected to have direct effects on restoring pancreatic b-cell function or insulin sensitivity, but recent studies suggest that these underlying defects could be improved via reduced glucotoxicity [30-32].”
Brown, A., Lang, C. C., McCrimmon, R. J., & Struthers, A. D. (2017) · BMC Cardiovascular Disorders · doi:10.1186/s12872-017-0663-6 · Cited by 34
“One such study showed that insulin mediated tissue glucose disposal increased by around 18% with only 2 weeks of dapagliflozin therapy [47].”
BackgroundRøder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 39
Hoenig, M. E., Clark, M., Schaeffer, D. J., & Reiche, D. (2017) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.12467 · Cited by 37
“In diabetics, the increase in EGP offsets about half of the amount of blood glucose, which is excreted into the urine by inhibiting SGLT2 (Cefalu, 2014; Ferrannini et al., 2014; Merovci et al., 2014).”
BackgroundPossibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor
Gu, N., Park, S., Chung, H., Jin, X., Lee, S., & Kim, T. (2020) · Translational and Clinical Pharmacology · doi:10.12793/tcp.2020.28.e4 · Cited by 38
Ottosson-Laakso, E., Tuomilehto, J., Forsén, B., Gullström, M., Groop, P., Groop, L., & Vikman, P. J. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146114 · Cited by 39
“Furthermore, it has been shown that inhibition of glucose reabsorption by SGLT2 inhibitors increases endogenous glucose production and plasma glucagon concentrations in diabetic subjects [11,12], and nondiabetic mice [13].”
BackgroundMartinussen, C., Veedfald, S., Dirksen, C., Bojsen-Møller, K. N., Svane, M. S., Albrechtsen, N. J. W., van Hall, G., Kristiansen, V. B., Fenger, M., Holst, J. J., et al. (2020) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00023.2020 · Cited by 34
McInnes, N., Hall, S., Sultan, F., Aronson, R., HRAMIAK, I. M., Harris, S. B., Sigal, R. J., Woo, V. C., Liu, Y., & Gerstein, H. C. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa248 · Cited by 39
Otsuka, H., Yokomizo, H., Nakamura, S., Izumi, Y., Takahashi, M., Obara, S., Nakao, M., Ikeda, Y., Sato, N., Sakamoto, R., et al. (2022) · Biochemical Journal · doi:10.1042/bcj20210700 · Cited by 38
“Evidence suggested that SGLT2 inhibitors improve the skeletal muscle insulin sensitivity [56,57].”
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes
Wang, M.-Y., Yu, X., Lee, Y., McCorkle, S. K., Chen, S., Li, J., Wang, Z. V., Davidson, J. A., Scherer, P. E., Holland, W. L., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705845114 · Cited by 35
Empagliflozin Reduces Liver Fat in Individuals With and Without Diabetes
Abdelgani, S., Khattab, A., Adams, J. M., Baskoy, G., Brown, M., Clarke, G., Larvenenko, O., DeFronzo, R. A., & Abdul‐Ghani, M. A. (2024) · Diabetes Care · doi:10.2337/dc23-1646 · Cited by 43
Self-citationSolis‐Herrera, C., Daniele, G., Alatrach, M., Agyin, C., Triplitt, C. L., Adams, J. M., Patel, R., Gastaldelli, A., Honka, H., Chen, X., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2177 · Cited by 32
Self-citationKashiwagi, A., Araki, S., & Maegawa, H. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13329 · Cited by 33
van Bommel, E. J. M., Geurts, F., Muskiet, M. H. A., Post, A., Bakker, S. J. L., Danser, A. H. J., Touw, D. J., van Berkel, M., Kramer, M. H. H., Nieuwdorp, M., et al. (2020) · Clinical Science · doi:10.1042/cs20201274 · Cited by 38
Singh, A. K., & Singh, R. (2022) · World Journal of Cardiology · doi:10.4330/wjc.v14.i6.329 · Cited by 35
Hwang, S. H., Kang, I., & Lim, S. S. (2017) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2017/4380721 · Cited by 49
Current Nutritional and Pharmacological Approaches for Attenuating Sarcopenia
Sakuma, K., Hamada, K., Yamaguchi, A., & Aoi, W. (2023) · Cells · doi:10.3390/cells12192422 · Cited by 39
Metadata
- Authors
- Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., & DeFronzo, R. A.
- Affiliations
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A.
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2014-01-27
- Volume
- 124
- Issue
- 2
- Pages
- 509-514
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3904617
- OpenAlex
- W2166613497
- Cited by
- 795
- References
- 28
- Citations by year
- 2026: 26 · 2025: 40 · 2024: 52 · 2023: 55 · 2022: 64 · 2021: 58 · 2020: 91 · 2019: 63 · 2018: 71 · 2017: 71 · 2016: 79 · 2015: 82 · 2014: 43
- FWCI
- 73.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Bristol-Myers Squibb
- National Institutes of Health (UL1TR001120, 5R01DK240923, KL2TR001118)
- University of Texas Health Science Center at San Antonio
- National Institute of Diabetes and Digestive and Kidney Diseases (5R01DK240923, R01DK024092)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, skeletal muscle insulin sensitivity, endogenous glucose production, glycosuria, glucotoxicity, hyperglycemia, insulin-stimulated glucose disposal, glucagon, renal glucose transport
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Glucagon, Glucose, Glucosides, Humans, Hyperglycemia, Insulin, Male, Metformin, Middle Aged, Muscles, Sulfonylurea Compounds, Time Factors, Glucose Clamp Technique, Sodium-Glucose Transporter 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.